BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (BEP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00586443|
Recruitment Status : Completed
First Posted : January 4, 2008
Last Update Posted : November 19, 2014
Targeting molecular pathways of tumor growth has become a major focus of anti-cancer treatments. This study aims to investigate the toxicity, pharmacokinetics, and preliminary efficacy of the triplet combination of bevacizumab, RAD001, and panitumumab in patients with refractory solid tumors.
This open-labeled, non-randomized phase I trial of bevacizumab, everolimus and panitumumab is designed to assess the safety, tolerability and efficacy of this combination in adult patients with advanced solid tumors.
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors||Drug: bevacizumab, everolimus, panitumumab||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of Bevacizumab, Everolimus, and Panitumumab for Patients With Advanced Solid Tumors|
|Study Start Date :||November 2007|
|Primary Completion Date :||September 2014|
|Study Completion Date :||September 2014|
This is a Phase I safety study. There is only one arm.
Drug: bevacizumab, everolimus, panitumumab
Cohort # subjects Bevacizumab Everolimus Panitumumab
- To determine the MTD/recommended phase II regimen and evaluate safety of panitumumab added to RAD001 plus bevacizumab in adult patients with advanced solid tumors. [ Time Frame: Every cycle (28-days) ]
- To preliminarily describe any clinical activity (PR, CR or duration of SD) associated with this regimen [ Time Frame: Every cycle (28-days) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586443
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Herbert I Hurwitz, MD||Duke University|